Becton DickinsonBDXEarnings & Financial Report
Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.
BDX Q1 FY2026 Key Financial Metrics
Revenue
$5.3B
Gross Profit
$2.4B
Operating Profit
$552.0M
Net Profit
$382.0M
Gross Margin
45.9%
Operating Margin
10.5%
Net Margin
7.3%
YoY Growth
-0.4%
EPS
$1.34
Becton Dickinson Q1 FY2026 Financial Summary
Becton Dickinson reported revenue of $5.3B (down 0.4% YoY) for Q1 FY2026, with a net profit of $382.0M (up 24.0% YoY) (7.3% margin). Cost of goods sold was $2.8B, operating expenses totaled $1.9B.
Key Financial Metrics
| Total Revenue | $5.3B |
|---|---|
| Net Profit | $382.0M |
| Gross Margin | 45.9% |
| Operating Margin | 10.5% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Becton Dickinson Q1 FY2026 revenue of $5.3B breaks down across 10 segments, led by Other at $2.8B (53.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $2.8B | 53.1% |
| Medication Management Solutions | $678.0M | 12.9% |
| Urologyand Critical Care | $339.0M | 6.5% |
| Surgery | $310.0M | 5.9% |
| Peripheral Intervention | $265.0M | 5.0% |
| Specimen Management | $245.0M | 4.7% |
| Advanced Patient Monitoring | $178.0M | 3.4% |
| Diagnostic Solutions | $176.0M | 3.4% |
| Bio Pharma Systems | $150.0M | 2.9% |
| Biosciences | $124.0M | 2.4% |
Becton Dickinson Revenue by Segment — Quarterly Trend
Becton Dickinson revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Medication Management Solutions) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Other | $2.8B | $3.4B | $1.4B | $1.2B |
| Medication Management Solutions | $678.0M | $678.0M | — | $709.0M |
| Urologyand Critical Care | $339.0M | $339.0M | $340.0M | $334.0M |
| Surgery | $310.0M | $310.0M | $289.0M | $294.0M |
| Peripheral Intervention | $265.0M | $265.0M | $274.0M | $271.0M |
Becton Dickinson Annual Revenue by Year
Becton Dickinson annual revenue history includes year-by-year totals (for example, 2025 revenue was $21.8B).
Becton Dickinson Quarterly Revenue & Net Profit History
Becton Dickinson results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $5.3B | -0.4% | $382.0M | 7.3% |
| Q4 FY2025 | $5.9B | +8.4% | $493.0M | 8.4% |
| Q3 FY2025 | $5.5B | +10.4% | $574.0M | 10.4% |
| Q2 FY2025 | $5.3B | +4.5% | $308.0M | 5.8% |
| Q1 FY2025 | $5.2B | +9.8% | $303.0M | 5.9% |
| Q4 FY2024 | $5.4B | +6.9% | $400.0M | 7.4% |
| Q3 FY2024 | $5.0B | +2.3% | $487.0M | 9.8% |
| Q2 FY2024 | $5.0B | +4.6% | $537.0M | 10.6% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.04B | $4.99B | $5.44B | $5.17B | $5.27B | $5.51B | $5.89B | $5.25B |
| YoY Growth | 4.6% | 2.3% | 6.9% | 9.8% | 4.5% | 10.4% | 8.4% | -0.4% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $54.16B | $55.58B | $57.29B | $54.66B | $54.47B | $54.90B | $55.33B | $54.84B |
| Liabilities | $28.51B | $29.71B | $31.40B | $29.46B | $29.23B | $29.43B | $29.93B | N/A |
| Equity | $25.65B | $25.87B | $25.89B | $25.20B | $25.24B | $25.47B | $25.39B | $25.28B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $514.0M | $1.30B | $1.18B | $693.0M | $164.0M | $1.22B | $1.35B | $657.0M |